Search
- All words: Returns only documents that match all words.
- Any word: Returns documents that match any word.
- Exact Phrase: Returns only documents that match the exact phrase entered.
- Phrase Prefix: Works like the Exact Phrase mode, except that it allows for prefix matches on the last term in the text.
- Wildcard: Returns documents that match a wildcard expression.
- Fuzzy query: Returns documents that contain terms similar to the search term. For example: If you search for Kolumbia. It will return search results that contain Columbia or Colombia.
Geek ElasticSearch powered by JoomlaGeek.com
  • Home
      • Back
      • Search our website
  • About Us
      • Back
      • Contact Dalgarno Institute
      • The Mission
      • The Niche
      • Become a Member Today
      • Donate Now
  • Advocacy
      • Back
      • Isabella's List
      • Dalgarno AOD Policy
      • People Against Drink/Drug Driving
      • Fence Builder
      • Monitoring Alcohol
      • Injecting Rooms
      • Back
      • Isabella's List Updates
      • Isabella's List Awards
      • Partner Resources
      • To Your Health
      • Become a member today
      • Foetal Alcohol Spectrum Disorders
  • Resources
      • Back
      • The Conundrum Continues Blog
      • Cannabis Conundrum
      • Research Reports
      • Research you can use
      • Drug Information Sheets
      • Partner Resources
      • Naltrexone
      • Radio Spots
      • Back
      • Cannabis & Your Community
      • Cannabis as Medicine?
      • Cannabis Resource Library
      • Media Releases
      • D.A.R.T. & Papers
      • Need Counselling
      • Dalgarno Video Blog
  • Education
      • Back
      • NoBrainer - Curriculum
          • Back
          • Curriculum
          • I Wish I Never DVD Curriculum
          • Party Girl DVD Curriculum
          • Humpty Dumpty Resiliency Education
      • Parent Program
      • AOD Educators
          • Back
          • Not even once!
          • Tony Hoang
          • Drug Free Lifestyle
          • D.E.A.S.Y AOD Ed
          • Save Your Brain - DFA
      • First Peoples
  • Give NoBrainer

POT Shop Exemption - 'Essential Service'? Addiction For Profit Model Exempt!

Details
01 April 2020
452

The Risk of Exempting Marijuana Businesses During COVID-19 Closures

WaitingForWeed

People stand in freshly painted circles, six-feet-apart, as they wait in a two-hour line to buy marijuana products from Good Chemistry on March 23, 2020 in Denver, Colorado. (Michael Ciaglo/Getty Images)

An Interview with an Emergency Department Physician in Colorado

I received a recent communication from Dr. Karen Randall, an emergency room physician in Pueblo, Colorado that is facing the outbreak of COVID-19, now straining its emergency services. Health care personnel are already short of resources, as Personal Protective Gear (PPE), capacity to test for the disease, and essential medical devices, such as ventilators, are in short supply.

The viral disease, when it strikes the most vulnerable, such as the elderly, the immunocompromised, or those with underlying co-morbidities, can progress rapidly from initial respiratory illness to profoundly impaired lung function, and death.

Adding to their wider public health threat, the town also has a large homeless population, often recent arrivals to Colorado, concentrated in make-shift encampments near town. Medical personnel are especially concerned with the spread of COVID and other infectious diseases in these encampments – many will become ill in a short period of time, resulting in a potential overload for an already-stressed health care system.

Colorado has issued orders to implement necessary closures and social-distancing practices. In particular, an appeal has been made to forestall non-emergency medical procedures, in an effort to preserve the functionality of hospitals, physician and nurses, and emergency departments, which are at the front lines of medical care responses.

In order to preserve scarce resources for essential personnel serving the most vulnerable at-risk patients, residents above all should take no actions that could hinder the emergency public health institutions struggling with the outbreak.

Businesses or operations deemed “essential” are provided exemption from the social restrictions meant to stave off a wider epidemic spread. Colorado is, of course, well-known for its commercial marijuana businesses. Remarkably, these very businesses have been deemed “essential” services by the state, and hence are exempt from closure.

Dr. Randall’s account warns of the risk caused by this exemption. Substantial percentages of the entire Colorado community are drug users, with concentrations of heavy marijuana users found in the homeless encampments, many of whom moved to Colorado because of their commercial market for high-potency marijuana and related products, such as concentrates and edibles.

The percentage of dependent daily drug users is growing, and has already stressed social services, including emergency hospital resources. By consuming high-potency concentrates, consumed by means of smoking, or propane/butane-fed flames, or by practicing dangerous vaping ingestion, this population has been routinely presenting to emergency services with the consequences of their addiction.

Compromised and damaged lungs. Cyclic vomiting, or hyper-emesis, requiring hospitalization. And repeated episodes of psychosis or mental derangement associated with consuming THC, the psychoactive component of marijuana, with intoxicated patients showing up time and again in the emergency department, behaving irresponsibly.

With the arrival of the highly contagious COVID virus, the risk presented by drug use is accelerating, increasing the stress on the system of emergency and intensive care, further taxing beleaguered physicians.

Doctor Randall describes her work this way:

We have been hit with COVID. It is just ramping up. Sadly, the decision here was to consider the marijuana businesses “essential.’ The lines to access the dispensaries have been extraordinary. Of course there is no “distancing.” People are buying products to smoke at a time when lungs are vulnerable. This means that the policy to keep marijuana shops open is counterproductive.

The drug users continue to come to the emergency department—cyclic vomiting, acute intoxications, etc. Not only do they “clog the ED wheels” they risk spreading COVID infection by coming to the ED. Seeking emergency care following a marijuana episode, patients present at the Emergency Department and thereby increase their own risk of exposure to the virus, as well as they risk becoming a vector of infection among others.

Personally, I have never been as concerned about going to work as I am now. I have seen intubated patients who had exposure and present clinical findings consistent with COVID. These people are frightened and are very sick. There are times when I feel overwhelmed because there are too many sick patients all at once.

As you know, there are significant PPE shortages. We have not been spared this problem. The fact that the marijuana stores would stay open is difficult to justify. It is medically stupid on many levels. The last thing the US needs is intoxicated drug users turning up with COVID pneumonia, adding to our at-risk senior population.

We already concerned about a shortage of ventilators and ICU beds. Should we add to this burden by enabling people to continue their intoxication? We see patients exposed to the virus through a known contact who begin to show symptoms, and then show up at the Emergency Department, but not before sharing a last bong with close friends before going to the hospital.

As you can see, hallucinogenic drug use leads to poor decisions. While intoxicated, drug users take unnecessary risks, endanger themselves and others, and then need help.

Emergency departments are packed with people already - we have the elderly, the smokers, the immunocompromised to deal with and we are inviting a subset of the population that should be healthy into this disaster—when, in fact, their lungs are no longer “young” or “healthy.”

There is finally the risk of users becoming immunocompromised with chronic excessive drug use. Early indications are that COVID causes injury to pulmonary structures. So, if a person is vaping and already altering the structure of lung tissue, this behavior compromises them even more, providing additional injury, less resistance to infection, and a greater likelihood of long-term consequences from both vaping and COVID.

The Colorado exemption for marijuana businesses represents a public policy mistake. The crazy part is that anyone would consider a hallucinogen a necessary medicine.

https://www.hudson.org/research/15868-the-risk-of-exempting-marijuana-businesses-during-covid-19-closures

COVID-19, Cannabis & Cardiovascular Risk

Details
30 March 2020
447

B.M.J - Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study

Apropos of the recent Covid-19 pandemic emergency it is also worth noting that since cannabis is immunosuppressive, is known to be damaging to lungs and airways and often carries chemical, microbial and fungal contaminants cannabis use and cannabis vaping is also likely to have a deleterious effect on the coronavirus epidemic.

Such data implies an untoward convergence of two public health epidemics. Appropriate controls on cannabis use imply improved public health management of SARS-CoV-2.

For complete data and response https://bmjopen.bmj.com/content/6/11/e011891.responses#response-to-lane

W.H.O, CBD and Challenging Misguided Recommendations

Details
30 March 2020
339

CADFY’s Statement to the Commission on Narcotic Drugs General Session - Vienna 2020

Regarding The World Health Organization’s recommendation 5.5

Recommendation 5.5: A footnote should be added to Schedule I of the 1961 Single Convention on Narcotic Drugs to read: “Preparations containing predominantly Cannabidiol (CBD) and not more than 0.2% of delta-9-THC are not under international control.

Thank you for giving me this time to speak before this distinguished body.

It is important to understand that CADFY has grave concerns regarding the World Health Organizations Recommendation 5.5

“In Recommendation 5.5, The Word Health Organization (WHO) and its Expert Committee on Drug Dependence (ECDD) have recommended that “preparations” containing predominantly CBD and not more than 0.2% THC be excluded from international control. The use of the term “preparation” will cause significant confusion, since, under the Single Convention, that term can apply to finished products. If WHO/ECDD had intended for their recommendation to apply only to drug substances or Active Pharmaceutical Ingredients, not to finished products, they had other terminology choices (such as the term “drug”) that would have caused less confusion, or they could have clearly explained their intention in the surrounding text. On the other hand, if WHO/ECDD did intend for their recommendation to apply to finished products, then the scientific justification on which they based the recommendation is mistaken. They relied almost exclusively on the abuse potential data from the Epidiolex studies (Epidiolex is the only purified CBD product to be approved as a prescription medication in the US and the EU.) However, in Epidiolex the finished product, the THC content is only 0.01% . By contrast, in the crystalline CBD drug substance or Active Pharmaceutical Ingredient of Epidiolex (before it is dissolved in sesame oil), the THC content is not more than 0.1% THC. So WHO/ECDD are potentially recommending the de-scheduling of products having 20 times more THC than Epidiolex. As you will see in the presentations, this can be a lot of THC.  In addition, in light of the poor quality control of the CBD products currently being marketed, there is no reliable way to ensure that products purporting to be pure CBD actually do not contain concerning levels of THC.  For these reasons, CADFY believes that Recommendation 5.5 should not be adopted in its current form. “

 

John Redman

Executive Director

Community Alliances for Drug Free Youth

 

CADFYLogo

Big Tobacco 2.O Seducing Oxford University??

Details
26 March 2020
298

Tobacco cash behind cannabis research in Oxford

BMJ 2020; 368  (Published 18 March 2020) Cite this as: BMJ 2020;368:m1044

A research collaboration that includes Oxford University is taking funding from the tobacco industry for research into the medicinal properties of cannabis. Jonathan Gornall continues his investigation into the links between big business and the push to widen cannabis access for patients.

The BMJ has uncovered links between companies, campaign groups and individuals lobbying for wider patient access to cannabis for medical use and a parallel campaign to create a lucrative recreational market for the drug in the UK. The first article focused on the links between commercial organisations that are seeking new markets for recreational cannabis and patient groups and researchers.1 Here, we look at the involvement of the tobacco industry in funding research into medicinal cannabis, and the complex web of connections linked to both medicinal and recreational use of cannabis.

Gavin Sathianathan is typical of the new breed of cannabis entrepreneur. The 41 year old is founder and main shareholder of Alta Flora, a private limited London based company, incorporated in May 2018, specialising in “wellness products from natural sources.”2 He is also a trustee of the United Patients Alliance (UPA), a patient led medical cannabis support group founded in 2014 to “safeguard the patients’ voice in advancing legal access to cannabis therapeutics.”3 The alliance is also supporting Project Twenty21, which aims to recruit and prescribe cannabis to 20 000 patients to create “the largest body of evidence for the effectiveness and tolerability of medical cannabis … to demonstrate to policymakers that medical cannabis should be as widely available, and affordable, as other approved medicines.”4

Another of Sathianathan’s recent roles was as chief executive of Forma Holdings, a cannabis investment fund launched in 2016 with offices in London and Los Angeles. Together with Neil Mahapatra, a contact from his student days at Harvard who is a managing partner at London based private equity and venture capital firm Kingsley Capital Partners, Sathianathan is also a co-founder and director of Oxford Cannabinoid Technologies.

In 2017 Kingsley announced that it was founding Oxford Cannabinoid Technologies and, in collaboration with Oxford University, investing up to £10m (€11m; $13m) in a “ground-breaking cannabinoid biomedicine research programme ... to investigate the role of cannabinoids in biology and medicine” and develop “safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions,” including cancer, pain, neurological conditions, and autoimmune and autoinflammatory diseases.5

But in June 2018 Oxford Cannabinoid Technologies announced it had attracted total additional funding of about $10m from two potentially controversial sources with investment interests that are not limited to the medicinal cannabis market.

One was Casa Verde Capital, a US venture capital firm co-founded in 2015 by Snoop Dogg, the US rap artist and high profile exponent of recreational cannabis use. 6 Casa Verde is focused exclusively on cannabis which, it believes, “will be among the most compelling investment themes of our generation.”7

The identity of the other investor—tobacco company Imperial Brands (formerly Imperial Tobacco)—will ring alarm bells in the public health community. In a press release in July 2018 announcing it was taking an equity stake in Oxford Cannabinoid Technologies, Imperial’s chief development officer, Matthew Phillips, said cannabinoid products had “significant potential and our investment enables Imperial to support OCT’s important research while building a deeper understanding of the medical cannabis market.”

Recreational market

Asked by The BMJ whether it had any plans to invest in any future recreational cannabis market in the UK, a spokesperson for Imperial dismissed this as “a hypothetical question.” He added: “Recreational cannabis is not legal in the UK and we have no plans. Any potential for changes to its legal status is a matter for the government, and we don’t have a view on this.”

A spokesperson for Oxford Cannabinoid Technologies told The BMJ that the company “would not look to enter the recreational market” should restrictions in the UK be eased. But he added: “It is worth noting that while neither [co-founder] Neil [Mahapatra] nor OCT advocate in support of recreational cannabis ... Kingsley Capital Partners has founded other businesses that are active in the cannabinoid market.”

However, in an interview in the Times newspaper in 2018 Mahapatra dismissed criticism of a healthcare company accepting money from a tobacco firm. “From my perspective,” he was quoted as saying, “any money that’s not going into developing cigarettes and is going into good things, such as research that could help people, is great.” The medical arguments for cannabis, he added, were “overwhelming or, at least, have the potential to be overwhelming.” He added he was “50/50” on whether cannabis should be legalised for recreational use.8

Marta Di Forti, a psychiatrist at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, who last year published research on the relation between cannabis use and psychotic disorder,9 called for more independent funding for cannabis research.

“It is always very dangerous to forget history and we are now seeing the sort of connections that we have seen happening before,” she said—and the involvement of tobacco company Imperial was “dreadful and shocking.”

“We are lacking in funding for cannabis research from independent organisations such as the Wellcome Trust or the Medical Research Council. The result will be that more and more you are going to see even prestigious and reputable academic institutions accepting money from some of these companies.”

For complete research

The Lancet - Single Dose of THC Could Induce Psychosis

Details
24 March 2020
523

The Lancet Psychiatry: Single dose of psychoactive component in cannabis could induce psychotic, depressive, and anxiety symptoms in healthy people

THE LANCET

  • In addition, the review found no consistent evidence that cannabidiol (CBD) moderates the effects of tetrahydrocannabinol (THC - the psychoactive component of cannabis) in healthy volunteers
  • Single dose of THC, roughly equivalent to smoking one joint, may induce a variety of psychiatric symptoms associated with schizophrenia and other psychiatric disorders. These effects are larger with intravenous administration than with inhaled administration, while tobacco smokers have fewer symptoms - though the authors stress that further work is needed to test this, and this finding should not be taken as a recommendation to use tobacco to counter the effects of THC.
  • These findings highlight the risks of cannabis use, which are highly relevant as medical, societal, and political interest in cannabinoids continues to grow.

A single dose of the main psychoactive component in cannabis, tetrahydrocannabinol (THC), can induce a range of psychiatric symptoms, according to results of a systematic review and meta-analysis of 15 studies including 331 people with no history of psychotic or other major psychiatric disorders, published in The Lancet Psychiatry journal. #weed #preventdontpromote

For complete research

Page 19 of 20

  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20

About Us

The Dalgarno Institute was named after a woman who was a key figure in the early reformation movements of the mid 19th Century. Isabella Dalgarno personified the spirit of a large and growing movement of socially responsible people who had a heart for both social justice and social responsibility....

read more

Get in Touch

PO Box 7005, Dandenong, Vic, 3175
1300 975 002
Contact Us
Online Store
© Dalgarno Institute.
Website and Hosting by PresData Services.
office use only

Search

Search
- All words: Returns only documents that match all words.
- Any word: Returns documents that match any word.
- Exact Phrase: Returns only documents that match the exact phrase entered.
- Phrase Prefix: Works like the Exact Phrase mode, except that it allows for prefix matches on the last term in the text.
- Wildcard: Returns documents that match a wildcard expression.
- Fuzzy query: Returns documents that contain terms similar to the search term. For example: If you search for Kolumbia. It will return search results that contain Columbia or Colombia.
Geek ElasticSearch powered by JoomlaGeek.com

Signup to the FenceBuilder Newsletter